Financial Results quarter ended 30th June 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Transgene Biotek reported a weak Q1 FY26 with revenue from operations flat at ₹4.95 lakhs (vs ₹4.92 lakhs in Q1 FY25), but total income collapsed 93% to ₹4.95 lakhs from ₹70.12 lakhs due to the absence of other income. Total expenses stood at ₹48.32 lakhs, while finance costs surged dramatically to ₹24.55 lakhs from just ₹1.73 lakhs a year ago — a roughly 14x jump suggesting a much higher debt burden. The company swung from a profit of ₹19.94 lakhs in Q1 FY25 to a loss of ₹43.37 lakhs, with EPS of ₹(0.06). The board also appointed a new internal auditor and a 5-year secretarial auditor, and extended the AGM date for FY24-25. A management note flags serious operational difficulties stemming from an ongoing SEBI adjudication matter (pending SAT hearing on 8 Sep 2025) and a fresh Enforcement Directorate appeal at the Appellate Tribunal, Delhi.
Shareholders face continued losses, surging interest costs, and regulatory headwinds from SEBI and ED proceedings — a clear going-concern overhang that is likely to keep the stock under pressure until the SAT/ED matters are resolved. The sharp jump in finance costs indicates rising debt stress, and the absence of any meaningful revenue base leaves little cushion.